Sequencing assays for failed genotyping with the versant hepatitis C virus genotype assay (LiPA), version 2.0.

ABSTRACT: For optimal antiviral therapy, the hepatitis C virus (HCV) genotype needs to be determined, as it remains a strong predictor of sustained viral response. In this study, we assessed the number of HCV genotyping results that could not be determined using the commercially available line probe assay (LiPA) (Versant hepatitis C virus genotype 2.0 assay) in a large international panel of samples from 9,874 HCV-positive patients. In-house sequencing assays targeting the 5' untranslated region (UTR), core region, NS3 region, and NS5B region of the HCV genome and phylogenetic analyses were used to resolve these LiPA failures. Among all cases, the genotypes of 51 samples (0.52%) could not be determined with the LiPA. These undetermined results were observed more frequently among samples from non-Eur

SUBMITTER: Larrat S 

PROVIDER: S-EPMC3754683 | biostudies-literature | 2013 Sep

REPOSITORIES: biostudies-literature